Niowave, Inc. and Ratio Therapeutics Sign Supply Agreement for Actinium-225 to Advance Targeted Alpha Therapies

LANSING, Mich. and BOSTON, June 16, 2026 /PRNewswire/ -- Niowave, Inc., a leading manufacturer of medical radioisotopes, and Ratio Therapeutics Inc. (Ratio), a clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment, today announced a supply agreement...